Description: BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Home Page: briacell.com
Bellevue Centre
West Vancouver,
BC
V7T 2X1
Canada
Phone:
604-921-1810
Officers
| Name | Title |
|---|---|
| Dr. William V. Williams M.D. | CEO, President & Director |
| Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. | CFO & Corporate Secretary |
| Dr. Miguel A. Lopez-Lago Ph.D. | Chief Scientific Officer |
| Dr. Giuseppe Del Priore M.D., M.P.H., MPH | Chief Medical Officer |
| Dr. Charles Louis Wiseman FACP, M.D. | Founder, Principal Research Advisor & Member of Scientific Advisory Board |
Exchange: TO
Country: CA : Canada
Currency: Canadian Dollar (C$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 16.9685 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |